NASDAQ: STROSutro Biopharma Inc Stock
$4.99+0.27 (+5.72%)
Updated Jun 5, 2023
STRO Price
$4.99
Fair Value Price
$5.65
Market Cap
$301.48M
52 Week Low
$3.33
52 Week High
$8.72
P/E
-2.1x
P/B
1.63x
P/S
3.64x
PEG
N/A
Dividend Yield
N/A
Revenue
$74.55M
Earnings
-$130.14M
Gross Margin
100%
Operating Margin
-163.08%
Profit Margin
-174.6%
Debt to Equity
0.93
Operating Cash Flow
-$22M
Beta
1.44
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
STRO Overview
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how STRO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
STRO ($4.99) is undervalued by 11.7% relative to our estimate of its Fair Value price of $5.65 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
STRO ($4.99) is not significantly undervalued (11.7%) relative to our estimate of its Fair Value price of $5.65 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
STRO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more STRO due diligence checks available for Premium users.
Be the first to know about important STRO news, forecast changes, insider trades & much more!
STRO News
Valuation
STRO fair value
Fair Value of STRO stock based on Discounted Cash Flow (DCF)
Price
$4.99
Fair Value
$5.65
Undervalued by
11.70%
STRO ($4.99) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
STRO ($4.99) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
STRO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
STRO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.1x
Industry
11.59x
Market
53.21x
STRO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.63x
Industry
5.21x
STRO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
STRO's financial health
Profit margin
Revenue
$12.7M
Net Income
-$50.1M
Profit Margin
-394.9%
STRO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
STRO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$358.0M
Liabilities
$172.6M
Debt to equity
0.93
STRO's short-term assets ($304.06M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
STRO's short-term assets ($304.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
STRO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$61.0M
Investing
$67.5M
Financing
$8.8M
STRO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
STRO vs Biotech Stocks
Sutro Biopharma Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.